Metabolic syndrome (MetS) is a pathological condition of a variety of metabolic abnormalities, which requires more urgent treatment and intervention.
Fucoidan has been recommended as a supplement for health enhancement and disease management. Here, we first propose that the beneficial effect of low molecular weight
fucoidan fraction LF2 in regulating
metabolic syndrome induced by high-fat diet is similar to that of
metformin, in terms of molecular mechanism and gut microbiota. The study found that LF2 significantly reduces fasting
blood glucose, enhances
insulin sensitivity and restores
insulin homeostasis and
lipid homeostasis. Moreover, LF2 reduced liver oxidative stress and
inflammation, and improved hepatocyte steatosis. To decipher the mechanism behind this
therapeutic effect, both the molecular mechanisms and gut microbiota were further analyzed. LF2 inhibited the activation of PI3K-Akt-mTOR axis and decreased the expression of
SREBP-1c and PPARĪ³ in liver. Interestingly, we found that LF2 and
metformin have similar effects on gut microbiota, increasing the proportion of Verrucomicrobia and enriching the abundance of Akkermansia muciniphila, which is beneficial to host health. Collectively, our research clarifies the new application of
fucoidan as a functional food for anti-MetS, and provides a new insight for
fucoidan to exert systemic
therapeutic effects from the perspective of molecular mechanism and gut microbiota.